Chronic myeloproliferative diseases (MPDs) are clonal hematopoietic stem cell disorders characterized by cytokine hypersensitivity and normal cell maturation. Recently, the constitutively active mutant of Janus kinase 2 (JAK2), V617F, has been found in MPDs. [1] [2] [3] [4] JAK2 located at 9p24 is a member of a family of tyrosine kinases involved in cytokine receptor signaling. 5 Development of acute leukemia is not common but one of the forms of terminal stage in MPDs. However, its additional molecular abnormalities have not been fully characterized. 
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In acute leukemia transformed from MPDs (N ¼ 7), we examined FLT3, N-RAS and p53 gene mutations, which were frequently found in de novo acute myeloid leukemia (AML) in addition to JAK2 gene mutation. Samples of mononuclear cells were obtained from peripheral blood or bone marrow cells stored in Nagoya University. All patients gave informed consent for study in accordance with the approval of the institutional ethics committee. We examined the JAK2 mutation by reverse transcription-PCR using the following primers: JAK2F: 5 0 -AAAGGCGTACGAAGAGAAGTAGGAG-3 0 and JAK2R: 5 0 -TCACTAAGTTTGATGAAAGGAGGAT-3 0 . The amplified 416-bp fragment was subjected to sequence analysis and restriction enzyme digestion with BsaXI. Mutations of FLT3, N-RAS and p53 genes were also analyzed as previously described. 6 JAK2 mutation was found in all of the seven patients with acute leukemia from MPDs (Table 1 ) but in none of de novo AML (N ¼ 65) and acute lymphoblastic leukemia (ALL) (N ¼ 16). UPN1 to five had homogeneous JAK2 mutations, and UPN3 showed del(20)(q?), which is coincident to homozygous mutation of JAK2. No common abnormality of karyotypes was identified, but structural abnormalities were found in five of the seven patients. Sequences of p53, N-RAS and FLT3 genes were wild type in the seven patients. Clinically, no patients achieved hematological remission after chemotherapy and their survival was 3-9 months after transformation.
JAK2 mutation reportedly involves myeloid but not lymphoid lineage. Leukemia transformation usually results in AML. Furthermore, JAK2 mutation has been reported in a small percentage of myeloid malignancies but not in lymphoid ones. 7 No JAK2 V617F mutation has been found in de novo AML and ALL in our study. However, UPN3 developed acute T-lymphoblastic leukemia (T-ALL) with CD2
After several courses of combination chemotherapy for T-ALL, the leukemia phenotype was changed to an undifferentiated type with
As lymphoblastic transformation from polycythemia vera (PV) is rare, it was difficult to distinguish whether the leukemia was related to PV. Existence of JAK2 mutation in T-ALL suggests that acute leukemia from MPDs may originate at a level of multipotential stem cell.
This study suggested that JAK2 mutation is a sole but specific mutation in acute leukemia from MPDs. It is needed to investigate the molecular second hit associated with the leukemic transformation in MPDs. 
